Area of Focus: Oncology

OncoLab develops ANGel (Antibody-Conjugated NanoGel), a bio-responsive hydrogel nanogel platform addressing unmet needs in TNBC and other hard-to-treat solid tumors in IO and broader diseases. By advanced formulation and targeted delivery, ANGel enables controlled-release of biologics, improves SC admin, and supports lifecycle extension. Backed by Korean gov’t grants and early VC, our team aims to co-develop with global pharma and expand global reach as Korea’s innovative biotech.